Evaxion Biotech A/S (EVAX) Stock Score, Valuation & Financial Research
Evaxion Biotech A/S is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for EVAX
Evaxion Biotech A/S currently has a Wall Street Score of 27/100. The stored market price is $3.04. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Evaxion Biotech A/S does
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
EVAX financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $3.04
- Market capitalization:
- $19.2M
- Revenue:
- $7.5M
- Net income:
- $-8.7M
- Free cash flow:
- $-6.7M
- Cash:
- $14.0M
- Total debt:
- $7.1M
- EPS:
- -6.13
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 24/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-6.7M, showing cash burn in the current stored period.
- The balance sheet shows $14.0M of cash versus $7.1M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: EVAX decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research EVAX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.